Literature DB >> 33669292

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.

Yu Toyoda1, Kateřina Pavelcová2,3, Jana Bohatá2,3, Pavel Ješina4, Yu Kubota1, Hiroshi Suzuki1, Tappei Takada1, Blanka Stiburkova2,4.   

Abstract

The ABCG2 gene is a well-established hyperuricemia/gout risk locus encoding a urate transporter that plays a crucial role in renal and intestinal urate excretion. Hitherto, p.Q141K-a common variant of ABCG2 exhibiting approximately one half the cellular function compared to the wild-type-has been reportedly associated with early-onset gout in some populations. However, compared with adult-onset gout, little clinical information is available regarding the association of other uricemia-associated genetic variations with early-onset gout; the latent involvement of ABCG2 in the development of this disease requires further evidence. We describe a representative case of familial pediatric-onset hyperuricemia and early-onset gout associated with a dysfunctional ABCG2, i.e., a clinical history of three generations of one Czech family with biochemical and molecular genetic findings. Hyperuricemia was defined as serum uric acid (SUA) concentrations 420 μmol/L for men or 360 μmol/L for women and children under 15 years on two measurements, performed at least four weeks apart. The proband was a 12-year-old girl of Roma ethnicity, whose SUA concentrations were 397-405 µmol/L. Sequencing analyses focusing on the coding region of ABCG2 identified two rare mutations-c.393G>T (p.M131I) and c.706C>T (p.R236X). Segregation analysis revealed a plausible link between these mutations and hyperuricemia and the gout phenotype in family relatives. Functional studies revealed that p.M131I and p.R236X were functionally deficient and null, respectively. Our findings illustrate why genetic factors affecting ABCG2 function should be routinely considered in clinical practice as part of a hyperuricemia/gout diagnosis, especially in pediatric-onset patients with a strong family history.

Entities:  

Keywords:  ABCG2 genotype; Roma; SUA-lowering therapy; clinico-genetic analysis; ethnic specificity; genetic variations; precision medicine; rare variant; serum uric acid; urate transporter

Mesh:

Substances:

Year:  2021        PMID: 33669292      PMCID: PMC7920026          DOI: 10.3390/ijms22041935

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  59 in total

1.  Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type?

Authors:  Yu Toyoda; Aki Sakurai; Yasumasa Mitani; Masahiro Nakashima; Koh-ichiro Yoshiura; Hiroshi Nakagawa; Yasuo Sakai; Ikuko Ota; Alexander Lezhava; Yoshihide Hayashizaki; Norio Niikawa; Toshihisa Ishikawa
Journal:  FASEB J       Date:  2009-04-21       Impact factor: 5.191

2.  Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.

Authors:  Hirotaka Matsuo; Tappei Takada; Kimiyoshi Ichida; Takahiro Nakamura; Akiyoshi Nakayama; Yuki Ikebuchi; Kousei Ito; Yasuyoshi Kusanagi; Toshinori Chiba; Shin Tadokoro; Yuzo Takada; Yuji Oikawa; Hiroki Inoue; Koji Suzuki; Rieko Okada; Junichiro Nishiyama; Hideharu Domoto; Satoru Watanabe; Masanori Fujita; Yuji Morimoto; Mariko Naito; Kazuko Nishio; Asahi Hishida; Kenji Wakai; Yatami Asai; Kazuki Niwa; Keiko Kamakura; Shigeaki Nonoyama; Yutaka Sakurai; Tatsuo Hosoya; Yoshikatsu Kanai; Hiroshi Suzuki; Nobuyuki Hamajima; Nariyoshi Shinomiya
Journal:  Sci Transl Med       Date:  2009-11-04       Impact factor: 17.956

3.  Novel homozygous insertion in SLC2A9 gene caused renal hypouricemia.

Authors:  Blanka Stiburkova; Kimiyoshi Ichida; Ivan Sebesta
Journal:  Mol Genet Metab       Date:  2011-01-04       Impact factor: 4.797

4.  Modern diagnostic approach to hereditary xanthinuria.

Authors:  Martin Mraz; Olha Hurba; Josef Bartl; Zdenek Dolezel; Anthony Marinaki; Lynette Fairbanks; Blanka Stiburkova
Journal:  Urolithiasis       Date:  2014-11-06       Impact factor: 3.436

5.  Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.

Authors:  Hiroshi Nakagawa; Kanako Wakabayashi-Nakao; Ai Tamura; Yu Toyoda; Shoko Koshiba; Toshihisa Ishikawa
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

6.  ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.

Authors:  R L Roberts; M C Wallace; A J Phipps-Green; R Topless; J M Drake; P Tan; N Dalbeth; T R Merriman; L K Stamp
Journal:  Pharmacogenomics J       Date:  2016-01-26       Impact factor: 3.550

Review 7.  Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.

Authors:  Mats Dehlin; Lennart Jacobsson; Edward Roddy
Journal:  Nat Rev Rheumatol       Date:  2020-06-15       Impact factor: 20.543

8.  Clinical characteristics of early- and late-onset gout: A cross-sectional observational study from a Chinese gout clinic.

Authors:  Bingqing Zhang; Weigang Fang; Xuejun Zeng; Yun Zhang; Ya Ma; Feng Sheng; Xinlei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 9.  Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.

Authors:  Yu Toyoda; Tappei Takada; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2019-03-05       Impact factor: 5.810

10.  Common dysfunctional variants in ABCG2 are a major cause of early-onset gout.

Authors:  Hirotaka Matsuo; Kimiyoshi Ichida; Tappei Takada; Akiyoshi Nakayama; Hiroshi Nakashima; Takahiro Nakamura; Yusuke Kawamura; Yuzo Takada; Ken Yamamoto; Hiroki Inoue; Yuji Oikawa; Mariko Naito; Asahi Hishida; Kenji Wakai; Chisa Okada; Seiko Shimizu; Masayuki Sakiyama; Toshinori Chiba; Hiraku Ogata; Kazuki Niwa; Makoto Hosoyamada; Atsuyoshi Mori; Nobuyuki Hamajima; Hiroshi Suzuki; Yoshikatsu Kanai; Yutaka Sakurai; Tatsuo Hosoya; Toru Shimizu; Nariyoshi Shinomiya
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  6 in total

1.  ABC Transporters in Human Diseases: Future Directions and Therapeutic Perspectives.

Authors:  Thomas Falguières
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

2.  Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

Authors:  Margarida L F Martins; Paniz Heydari; Wenlong Li; Alejandra Martínez-Chávez; Nikkie Venekamp; Maria C Lebre; Luc Lucas; Jos H Beijnen; Alfred H Schinkel
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

Review 3.  Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.

Authors:  Teodora Constantinescu; Alin Grig Mihis
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

Review 4.  The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.

Authors:  Robert Eckenstaler; Ralf A Benndorf
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

5.  Medical Students' Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study.

Authors:  Sanja Zuzic Furlan; Doris Rusic; Marko Kumric; Josko Bozic; Marino Vilovic; Tina Vilovic; Marko Rada; Venija Cerovecki; Marion Tomicic
Journal:  Healthcare (Basel)       Date:  2021-11-26

Review 6.  Hypouricemia and Urate Transporters.

Authors:  Naoyuki Otani; Motoshi Ouchi; Kazuharu Misawa; Ichiro Hisatome; Naohiko Anzai
Journal:  Biomedicines       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.